Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Prostate-specific membrane antigen (PSMA) agents have shown promise in detecting and treating
prostate cancer. Gallium-68-labeled PSMA-11 (68Ga-PSMA-11) is a radioactive agent that binds
to prostate cancer cells and can be imaged using positron emission tomography (PET) scanners
that detect radioactivity in the body. This early phase I study will use PET to determine if
delivering 68Ga-PSMA-11 directly into the prostatic artery (intra-arterial (IA)
administration) results in greater uptake in the prostate than delivering 68Ga-PSMA-11 into a
vein in the arm (intravenous (IV) administration).